Andere Sprachen Medexus Pharmaceuticals Inc.

Aktien

A2PA3U

CA58410Q2036

MDP

Markt geschlossen - Toronto S.E. Andere Börsenplätze 21:59:59 17.05.2024			% 5 Tage	% 1. Jan.
1,6 ^CAD	-1,23 %		+0,63 %	-35,22 %

26.03.	Medexus Pharmaceuticals gibt bekannt, dass die US Food and Drug Administration den ergänzenden Lizenzantrag für IXINITY(R) genehmigt hat	CI
09.02.	MEDEXUS PHARMACEUTICALS INC. : Stifel GMP bekräftigt seine Kaufempfehlung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Federal Court Finds Patent For Concentrated Methotrexate Solutions Obvious	07.05.
Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada	01.05.
Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference	02.04.
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY to Treat Hemophilia B in Pediatric Patients	27.03.
Medexus Pharmaceuticals Announces US Food and Drug Administration Approves It's Supplemental Biologics License Application for IXINITY(R)	26.03.
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients	26.03.
Medexus Pharmaceuticals Down 30% After Announces Fiscal Q3 2024 Results	08.02.
Medexus Pharmaceuticals Announces Fiscal Q3 2024 Results	08.02.
Medexus Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	08.02.
Medexus Announces Fiscal Q3 2024 Results	07.02.
North American Morning Briefing : Stock Futures Hold Line Ahead of More Earnings, Fedspeak	07.02.
Medexus Schedules Third Fiscal Quarter 2024 Conference Call	30.01.
Medexus Pharmaceuticals - Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine	09.01.
Medexus Pharmaceuticals Says Health Canada to Review New Drug Submission for Topical Terbinafine	08.01.
Medexus Pharmaceuticals Announces Health Canada Accepts for Review Medexus's New Drug Submission, or NDS, for Terbinafine Hydrochloride Nail Lacquer to Treat fungal N Infections	08.01.
Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine	08.01.
Medexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 Million	08.11.
Medexus Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	08.11.
Medexus Schedules Second Fiscal Quarter 2024 Conference Call	01.11.
Medexus Announces Full Exercise and Closing of Over-Allotment Option in Bought-Deal Public Offering	17.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Medexus Pharmaceuticals Inc.

Aktien

A2PA3U

CA58410Q2036

MDP

Andere Sprachen

Filter